The reforms respond to faster and lower-cost trial starts in China that have attracted US biotech companies to move their research programmes overseas.
Observers are watching the situation closely for further developments.
More details are likely to emerge as the situation continues to develop.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources: